Incidence and severity of new onset diabetes associated with SARS-CoV-2 infection

与 SARS-CoV-2 感染相关的新发糖尿病的发病率和严重程度

• 批准号: 10632720
• 负责人: JANE E REUSCH
• 金额: $ 40.6万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10632720
• 关键词: 2019-nCoV; Acute; Address; Adrenal Cortex Hormones; Adult; Affect; Autoimmune; Biochemical Markers; Body mass index; COVID-19; COVID-19 impact; COVID-19 pandemic; COVID-19 patient; COVID-19 severity; Caring; Data; Data Analytics; Data Set; Diabetes Mellitus; Diabetic Ketoacidosis; Diagnosis; Disease; Disease remission; Dyslipidemias; Endothelium; Geography; Glucose; Glycosylated hemoglobin A; Goals; Health Insurance Portability and Accountability Act; Healthcare; Hypertension; Iatrogenesis; Incidence; Infection; Inflammation; Inflammatory; Injury; Inpatients; Insulin; Insulin Resistance; Lipids; Longterm Follow-up; Measurement; Medical Informatics; Natural Immunity; Outcome; Patient risk; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Population; Positioning Attribute; Prognosis; Publishing; Recording of previous events; Research; Risk; SARS-CoV-2 infection; Severities; Site; Structure of beta Cell of islet; Testing; Time; United States National Institutes of Health; Upper Respiratory Infections; Vaccination; Variant; Virus; Work; analytic epidemiology; base; clinical phenotype; clinically significant; cohort; comorbidity; coronavirus disease; data enclave; demographics; diabetogenic; epidemiology study; glycemic control; health care economics; high risk; indexing; male; multidisciplinary; pandemic disease; pediatric patients; post SARS-CoV-2 infection; response; social health determinants; statistics; theories

We of and will use data from t he National COVID Cohort Collaborative (N3C) to “conduct an epidemiologic study diabetes incidence and severity at onset and its potential association with the COVID-19 pandemic the causative virus SARS-CoV-2”The N3C data enclave is the largest publicly available HIPAA-limited data set in U.S. history, over 13 million patients from 72 contributing sites. Due to its scale, demographic and geographic diversity of inpatient and ambulatory data, N3C is uniquely suited to address our research objectives. Hypothesis: COVID-19 infection is associated with an increased incidence of diabetes and severe disease presentation, and there are patient- and infection-related factors that increase patient risk and impact long-term outcomes. Specific Aim 1: Test the hypothesis that COVID-19 infection and infection- related factors are associated with increased incidence of diabetes and severe presentation at diagnosis. We will examine the effect of COVID-19 and infection-related factors, including COVID-19 disease severity, corticosteroid treatment, biochemical markers and virus variant (based on timing in the pandemic or direct measurement), in adult and pediatric patients. We will analyze time to incident diabetes and association of infection-related factors in patients with COVID-19 infection compared to matched controls with acute upper respiratory infection (AURI). Specific Aim 2: Test the hypothesis that COVID-19 infection and patient- related factors are associated with increased incidence of diabetes and severe presentation at diagnosis. We will explore the effect of patient-related factors, including demographics, BMI, HbA1c and lipids prior to COVID-19, comorbidities (e.g., dyslipidemia, hypertension, autoimmune/inflammatory conditions), vaccination status, medication use and social determinants of health (SDOH) on incident diabetes and severe disease presentation in adult and pediatric patients with COVID-19 and matched controls with acute upper respiratory infection (AURI). Specific Aim 3: Test the hypothesis that patients with incident diabetes after COVID-19 will have worse long-term outcomes compared to those without COVID-19 infection. We will compare outcomes in adult and pediatric patients with incident diabetes diagnosed within 90 days of their index date with prior COVID-19 infection compared to matched controls with AURI. Long-term outcomes over 12-18 months will include diabetes remission, glycemic control and treatment with insulin and other glucose lowering medications. Impact: The NIH-supported N3C Data Enclave, with its demographic and geographic diversity, was created precisely to address the long-term consequences of the pandemic. The proposed studies will 1. Establish and characterize increased incidence and severity of diabetes with COVID-19 infection; 2. Elucidate infection- and patient-related factors associated with incident diabetes and severe disease presentation at diagnosis, and 3. Evaluate the long-term outcomes of patients with incident diabetes in a nationally representative population.

我们 的 和 将使用来自国家共同队列合作（N3C）的数据来进行流行病学研究 发作时糖尿病的发病率和严重程度及其与Covid-19大流行的潜在关联 病毒病毒SARS-COV-2” N3C数据飞地是最大的公开可用的HIPAA限制 美国历史上的数据设置，来自72名贡献场所的1300万患者。由于其规模，人口统计和 住院和门诊数据的地理多样性，N3C非常适合解决我们的研究目标。 假设：COVID-19感染与糖尿病的发生率增加有关 疾病表现，并且存在与患者和感染相关的因素，以增加患者的风险和 影响长期结果。特定目标1：检验COVID-19感染和感染的假设 相关因素与糖尿病事件增加和诊断时严重表现有关。 我们将研究COVID-19和与感染相关因素的影响，包括COVID-19疾病严重程度， 皮质类固醇治疗，生化标记和病毒变体（基于大流行或直接的时间） 测量），成人和儿科患者。我们将分析时间到事件糖尿病和关联 与急性上部的匹配对照相比 呼吸道感染（AURI）。特定目标2：检验COVID-19感染和患者的假设 相关因素与糖尿病事件增加和诊断时严重表现有关。 我们将探讨与患者相关因素的影响，包括人口统计学，BMI，HBA1C和脂质之前 COVID-19，合并症（例如血脂异常，高血压，自身免疫/炎症状况），疫苗接种 对糖尿病和严重疾病的健康状况，药物使用和社会决定者（SDOH） 与急性上呼吸道的成年和儿科患者的介绍和儿科患者及其匹配的对照 感染（Auri）。特定目的3：检验以下假设：Covid-19之后的入射糖尿病患者 与没有共同感染的那些相比，长期结局将更糟糕。我们将比较 成人和儿科患者在索引日期的90天内诊断的成人和儿科患者的结果 与AURI匹配的对照相比，先前的Covid-19感染。超过12-18个月的长期结局将 包括糖尿病的缓解，用胰岛素和其他葡萄糖降低药物治疗的血糖控制和治疗。 影响：创建了NIH支持的N3C数据飞地，其人口统计学和地理多样性被创建了 精确地解决了大流行的长期后果。拟议的研究将1。建立和 表征糖尿病患有COVID-19感染的发病率和严重程度的增加； 2。阐明感染和 与患者相关的因素与入射糖尿病和诊断时严重疾病的表现有关，3。 评估全国代表性人群中入射糖尿病患者的长期结局。